Consistently, we find that knockdown of SOX10, the upstream regulator of FOXD3 also sensitizes mutant BRAF melanoma cells to Vemurafenib in vitro and in vivo, suggesting that SOX10 can protect melanoma cells against the acute cytotoxic effect of RAF inhibitors. Here, FOXD3 is linked to melanoma.